debrisoquin has been researched along with caffeine in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (13.33) | 18.7374 |
| 1990's | 12 (40.00) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Henschel, L; Hoffmann, A | 1 |
| Henschel, L; Hoffmann, A; Sigusch, H | 1 |
| Henschel, L; Hoffmann, A; Huster, A; Jorke, D; Kraul, H; Reinhardt, M; Töpfer, R; Truckenbrodt, J | 1 |
| Crom, WR; Evans, WE; Meyer, WH; Mirro, J; Petros, WP; Relling, MV | 1 |
| Drakoulis, N; Heinemeyer, G; Koch, M; Loddenkemper, R; Minks, T; Nitz, M; Otte, F; Ploch, M; Roots, I | 1 |
| Bechtel, PR; Bechtel, YC; Grandmottet, M; Joanne, C | 1 |
| Bounameaux, Y | 1 |
| Arvela, P; Mustajoki, P; Mustajoki, S; Pelkonen, O; Rautio, A | 1 |
| Alm, C; Bertilsson, L; Carrillo, JA; Dahl, ML; Rodríguez, I; Svensson, JO | 1 |
| Hoffmann, A; Lautenschlager, MT; Müller, UA; Viktor, S | 1 |
| Adedoyin, A; Branch, RA; Frye, RF; Matzke, GR; Porter, JA | 1 |
| Adedoyin, A; Branch, RA; Frye, RF; Mauro, K | 1 |
| Fujita, S; Funae, Y; Imaoka, S; Kazusaka, A; Maeda, Y; Masuda, M; Morita, K | 1 |
| Bertilsson, L; Böttiger, Y; Brynne, N; Hallén, B | 1 |
| Lewis, IA; Palmer, J; Pleasance, S; Scott, RJ | 1 |
| Adedoyin, A; Branch, RA; Frye, RF; Romkes, M; Wilson, JW | 1 |
| Dickins, M; Gibson, A; Palmer, JL; Pleasance, S; Scott, RJ | 1 |
| Branch, RA; Frye, RF | 1 |
| Andersson, K; Bertilsson, L; Carrillo, JA; Christensen, M; Dahl, ML; Mihara, K; Ramos, SI; Tybring, G; Yasui-Furokori, N | 1 |
| Aherne, Z; Blakey, GE; Lockton, JA; Norwood, P; Perrett, J; Plume, J; Russell, M | 1 |
| Carrier, J; Edwards, DJ; Gardner, SF; Gentry, WB; Gurley, BJ; Hubbard, MA; Khan, IA; Shah, A; Williams, DK | 1 |
| Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C | 1 |
| Branch, RA; Chaves-Gnecco, D; Frye, RF; Matzke, GR; Rabinovitz, M; Shaikh, OS; Zgheib, NK | 1 |
| Branch, RA; Frye, RF; Romkes, M; Tracy, TS; Zgheib, NK | 1 |
| Fuhr, U; Jetter, A; Kirchheiner, J | 1 |
| Berka, K; Otyepka, M; Paloncýová, M | 1 |
1 review(s) available for debrisoquin and caffeine
| Article | Year |
|---|---|
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
Topics: Administration, Oral; ATP-Binding Cassette Transporters; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Pharmaceutical Preparations; Phenotype; Theophylline; Tolbutamide | 2007 |
10 trial(s) available for debrisoquin and caffeine
| Article | Year |
|---|---|
[Comparison of serum concentrations of caffeine, 4-methylaminoantipyrine, sulfamethazine and debrisoquin following oral administration of these substances as a cocktail in type II diabetics before and after insulin therapy].
Topics: Adult; Aged; Anti-Infective Agents; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 Enzyme System; Debrisoquin; Diabetes Mellitus, Type 2; Dipyrone; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin; Isoenzymes; Male; Middle Aged; Pyrazolones; Sulfamethazine; Sympatholytics | 1996 |
Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Topics: Adult; Analysis of Variance; Arylamine N-Acetyltransferase; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Interactions; Humans; Male; Mephenytoin; Phenotype; Reference Values | 1997 |
Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Topics: Adult; Anti-Ulcer Agents; Antihypertensive Agents; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Cresols; Cross-Over Studies; Cytochromes; Debrisoquin; Drug Interactions; Humans; Male; Muscarinic Antagonists; Omeprazole; Phenylpropanolamine; Polymorphism, Genetic; Tolterodine Tartrate; Urinary Bladder Diseases | 1999 |
An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cross-Over Studies; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Debrisoquin; Diclofenac; Drug Interactions; Female; Humans; Male; Mephenytoin; Midazolam; Muscle Relaxants, Central; Oxidoreductases, N-Demethylating | 2001 |
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Topics: Adrenergic Agents; Adult; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Male; Middle Aged; Omeprazole; Selective Serotonin Reuptake Inhibitors | 2002 |
Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
Topics: Adult; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Debrisoquin; Drug Combinations; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Plasma; Tolbutamide | 2004 |
In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.
Topics: Adrenergic Agents; Adult; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Citrus; Cytochrome P-450 Enzyme System; Debrisoquin; Dietary Supplements; Drug Interactions; Echinacea; Female; GABA Modulators; Humans; Isoenzymes; Kinetics; Male; Midazolam; Phenotype; Plant Extracts; Serenoa; Silybum marianum; Solubility | 2004 |
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger | 2005 |
Liver disease selectively modulates cytochrome P450--mediated metabolism.
Topics: Administration, Oral; Adult; Anticonvulsants; Antihypertensive Agents; Caffeine; Case-Control Studies; Chlorzoxazone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Isoenzymes; Liver Diseases; Male; Mephenytoin; Middle Aged; Muscle Relaxants, Central; Phosphodiesterase Inhibitors; Severity of Illness Index; Theophylline | 2006 |
Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Topics: Administration, Oral; Adolescent; Adult; Aged; Caffeine; Chlorzoxazone; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Therapy, Combination; Female; Flurbiprofen; Genotype; Humans; Isoenzymes; Male; Mephenytoin; Middle Aged | 2006 |
19 other study(ies) available for debrisoquin and caffeine
| Article | Year |
|---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
[Assessment of biotransformation capacity following oral administration of various model substances as cocktail].
Topics: Acetylation; Administration, Oral; Adult; Biotransformation; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Dipyrone; Humans; Hydroxylation; Liver; Male; Phenotype; Sulfamethazine | 1991 |
[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination].
Topics: Adult; Biotransformation; Caffeine; Debrisoquin; Dipyrone; Humans; Indocyanine Green; Liver; Liver Circulation; Male; Nifedipine; Sulfamethazine; Verapamil | 1991 |
[Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases].
Topics: Biotransformation; Caffeine; Debrisoquin; Dipyrone; Fatty Liver, Alcoholic; Female; Hepatitis, Chronic; Humans; Liver; Liver Cirrhosis, Alcoholic; Liver Diseases, Alcoholic; Liver Function Tests; Male; Metabolic Clearance Rate; Sulfamethazine | 1990 |
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.
Topics: Acetylation; Adolescent; Caffeine; Child; Child, Preschool; Chromatography, High Pressure Liquid; Debrisoquin; Dextromethorphan; Dextrorphan; Female; Humans; Isoquinolines; Levorphanol; Male; Oxidation-Reduction; Pediatrics; Phenotype | 1989 |
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Topics: ABO Blood-Group System; Acetylation; Acetyltransferases; Arylamine N-Acetyltransferase; Caffeine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Lung Neoplasms; Mixed Function Oxygenases; Phenotype; Polymorphism, Genetic; Risk Factors | 1988 |
The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype.
Topics: Acetylation; Adult; Caffeine; Debrisoquin; Diabetes Mellitus, Type 1; Female; Humans; Isoquinolines; Male; Middle Aged; Oxidation-Reduction; Phenotype | 1988 |
[Studies on the effect of various substances on platelet function with several methods].
Topics: Amphetamine; Anti-Anxiety Agents; Blood Platelets; Caffeine; Chlorpromazine; Debrisoquin; Dibenzazepines; Flurazepam; Guanethidine; Humans; Oxazoles; Papaverine; Phenytoin; Platelet Aggregation; Pyridines; Theophylline | 1973 |
Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men.
Topics: Adult; Arginine; Caffeine; Coumarins; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Heme; Humans; Isoenzymes; Lidocaine; Male; Middle Aged; Porphyrias, Hepatic; Reference Values | 1994 |
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Topics: Adrenergic Agents; Adult; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Debrisoquin; Female; Fluvoxamine; Humans; Male; Middle Aged; Reference Values; Selective Serotonin Reuptake Inhibitors; Smoking | 1996 |
Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.
Topics: Adult; Analysis of Variance; Antimalarials; Caffeine; Chloroquine; Chlorzoxazone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Drug Interactions; Humans; Isoenzymes; Male; Phenotype | 1998 |
Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Rapid metabolism of caffeine in debrisoquine poor metabolizer model rats.
Topics: Aging; Animals; Aryl Hydrocarbon Hydroxylases; Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Debrisoquin; Dexamethasone; Female; Humans; Hydroxylation; Male; Methylcholanthrene; Microsomes, Liver; Oxidoreductases, N-Demethylating; Phenobarbital; Pregnenolone Carbonitrile; Rats; Rats, Wistar; Sex Characteristics; Species Specificity; Troleandomycin; Uric Acid | 1998 |
Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry.
Topics: Automation; Caffeine; Chlorzoxazone; Chromatography, Gas; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Debrisoquin; Diclofenac; Glucuronidase; Humans; Indicators and Reagents; Midazolam; Reproducibility of Results; Sensitivity and Specificity; Substrate Specificity; Theophylline | 1999 |
In vivo modulation of CYP enzymes by quinidine and rifampin.
Topics: Acetylation; Administration, Oral; Adrenergic alpha-Antagonists; Adult; Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Quinidine; Reference Values; Rifampin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline | 2000 |
Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Disulfiram; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Male; Mephenytoin; Mixed Function Oxygenases; Time Factors | 2002 |
Molecular insight into affinities of drugs and their metabolites to lipid bilayers.
Topics: Caffeine; Cell Membrane; Chlorzoxazone; Coumarins; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Ibuprofen; Lipid Bilayers; Molecular Dynamics Simulation; Pharmaceutical Preparations; Phosphatidylcholines; Phosphatidylglycerols; Thermodynamics; Xenobiotics | 2013 |